This collection is approved as it pertains to the previous rule approved in 1993. OMB files comment on this collection as it pertains to the new proposed rule, and FDA will resubmit this collection with any changes along with the final rule. In drafting the final rule and paperwork submission, FDA should consider uses of appropriate technology (e.g. electronic submission of information) that could reduce burden. This collection was used without OMB approval by FDA in conjunction with a previous rule. FDA will take steps to ensure that this does not happen with future collections.
Inventory as of this Action
Requested
Previously Approved
05/31/2003
05/31/2003
10,175,490
0
0
2,790,693
0
0
0
0
0
Manufacturers receiving FDA orders to track a device, whose failure would likely have serious adverse health consequences, and which is implanted in humans for more than 1 year, or is life-sustaining or life-supporting and used outside a device user facility, are required to collect/maintain current tracking information about the identity and location of the device during distribution, and about the identity and location of patients receiving the device, including certian physician information. Distributors must report this date to manufacturers. Such information must be made available by manufacturers within 3 or..
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.